Can a talk therapy that boosts Self-Understanding prevent suicide?
NCT ID NCT07717320
First seen Jul 21, 2026 · Last updated Jul 28, 2026 · Updated 3 times
Summary
This study tests whether a type of psychotherapy called mentalization-based therapy (MBT) can help adults who are at risk of suicide. Participants have recent suicidal thoughts or behaviors along with depression or anxiety. The therapy aims to improve how people understand their own and others' mental states, which may reduce suicidal feelings and improve emotional regulation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mentalization-based therapy (MBT), a type of psychotherapy that helps people understand their own and others' thoughts and feelings
- What this could lead to
- If successful, this could provide an evidence-based therapy for suicide prevention that can be used in public health systems.
- What could go wrong
- This is a validation study, not a large-scale trial, so results may not apply broadly. The therapy requires trained therapists, which may limit access.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age and consent * Presence of suicidal ideation or active behavior in the last month, assessed using the C-SSRS (e.g., intentional ideation, plan, or preparatory behavior) * Depressive or anxious symptoms (Score ≥ 10 on the PHQ-9, indicating at least moderate depressive symptoms, or Score ≥ 10 on the GAD-7, suggesting clinically significant anxiety.) * Availability and commitment to participate in the full assessment using all the aforementioned scales. Exclusion Criteria: * Clinical Safety (exclude and refer immediately) * Imminent suicide risk according to the C-SSRS (e.g., attempt within the last 7 days, current intentional plan, access to lethal means, and low ambivalence). * PHQ-9 item 9 = 3 ("almost every day") with clinical corroboration of imminent risk. * Current self-harm with lethality/high-harm moderator requiring acute restraint. * Refusal to establish a safety plan or allow emergency contact. * Acute Psychiatric Conditions/Contraindications of Assessment * Active psychosis or unstabilized manic episode. * Substance use disorder in intoxication or acute withdrawal (e.g., last 24-72 hours) that precludes valid assessment. * Uncontrolled risk of severe other-directed violence. * Medical or neurological conditions that preclude valid participation * Severe cognitive impairment (e.g., dementia, recent moderate-to-severe traumatic brain injury) that prevents understanding/answering scales. * Decompensated medical illness (e.g., desaturation, delirium, severe uncontrolled pain). * Unstable neurological condition (e.g., uncontrolled seizures). * Methodological interferences * Recent changes in baseline psychotropic medications within the last 2 weeks. * Concurrent intensive psychotherapy initiated within the last 4 weeks. * Simultaneous participation in another trial that could contaminate results. * Language other than that of the scales without available validation. * Logistical impossibility for follow-up (no telephone/stable contact; imminent relocation plan). * Legal aspects/consent * Incapacity to consent (legal or clinical) and no available representative. * Legal restrictions that prevent participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Suicide risk are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Consultorio Inter Cambio
Panama City, Provincia de Panamá, Panama
-
Panama City Health Ministry Clinics
Panama City, Provincia de Panamá, Panama
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can data sharing prevent suicide among Jail-Cycling individuals?
- Writing away the pain: Text-Based therapy tested for suicidal youth
- App + therapy shows promise in cutting suicide risk for eating disorder patients
- Could a One-Hour talk save lives? new trial tests crisis planning for soldiers with brain injury
- NIH launches Decade-Long Check-In on depression and suicide risk
- New study seeks to unravel the roots of suicidal thoughts